The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Ribavirin Reduces Absolute Lymphocyte Counts in Hepatitis C Virus-Infected Patients Treated With Interferon-Free, Direct-Acting Antiviral Regimens
Harrington PR1, Fleischer R1, Connelly SM1, Lewis LL1, Murray J1. Clin Infect Dis. 2015 May 28. pii: civ419. [Epub ahead of print]
Author information
1Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
Abstract
In clinical trials of interferon-free, direct-acting antiviral treatment of chronic hepatitis C, subjects who received ribavirin had reduced lymphocyte levels (median decline of approximately 0.4-0.5 × 109 cells/L). A modest decline in CD4+ T cells was observed in subjects with human immunodeficiency virus type 1 coinfection without documented opportunistic infections.